Re-evaluating Treatment Targets in Acne Vulgaris: Adapting to a New Understanding of Pathophysiology
June 2014 | Volume 13 | Issue 6 | Supplement | s57 | Copyright © 2014
Leon H. Kircik MD
Indiana University School of Medicine, Indianapolis, IN
Icahn School of Medicine at Mount Sinai, New York, NY
Physicians Skin Care, PLLC, Louisville, KY
Two primary factors are changing current approaches to the management of acne vulgaris (AV): the continuously evolving role of
Propionibacterium acnes in the pathophysiology of AV and recent evidence of an inflammatory basis for AV via innate immunity. The
developing concepts emphasize that acne is primarily an inflammatory disease. The emerging concept of subclinical inflammation
and its effect on development and progression of acne lesions correlating with the sequence of the underlying inflammation process
has been a major change in our understanding of acne pathogenesis. Thus, inflammation has become the major feature of the disease
process from onset to resolution, including postinflammatory erythema, postinflammatory hyperpigmentation, and scarring.
Our treatment targets may also need to be reconsidered, with more emphasis on anti-inflammatory treatments.
J Drugs Dermatol. 2014;13(suppl 6):s57-s60.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Two primary factors are changing current approaches to the management of acne vulgaris (AV): the continuously evolving role of Propionibacterium acnes in the pathophysiology of AV and emerging evidence of an inflammatory basis for AV. The developing concepts emphasize that acne is primarily an inflammatory disease. Recent research has confirmed that inflammation is the hallmark of all acne lesions, from the microcomedo to so-called “noninflammatory” lesions (open and closed comedones), to inflammatory lesions (papules, pustules, nodules, and "cysts"), to “postinflammatory” erythema and hyperpigmentation and scarring.
The pathophysiology of acne and associated scarring were elucidated with reports of marked elevations in inflammatory cytokine gene transcripts in active acne lesions, including tumor necrosis factor (TNF)-α and interleukin (IL)-1β, leading to an amplification of nuclear factor (NF)-kB signaling pathways. There were also significant increases in IL-8 and IL-10 and elevated activator protein (AP)-1 in acne lesions. This leads to elevated matrix metalloproteinases, which degrade collagen up to 2.5 fold compared with normal skin. Moreover, this inflammatory process was localized to the pilosebaceous unit.1
Given these findings, clinicians are re-evaluating their therapeutic targets in the pathogenesis of AV and exploring optimal regimens that reduce inflammation without contributing to antibiotic resistance.
A History of Inflammation
There was no doubt that inflammation played an important role in the development of inflammatory lesions, such as papules and pustules, or that P. acnes played a role leading to secondary inflammatory processes in those stages of acne development. Recent research has elucidated the role of inflammation in the pathogenesis of acne and, more precisely, the contribution of P. acnes to drive inflammation.1-9 It was already well established that acne is not an infectious process.2 P. acnes is now shown to drive the inflammation of AV via various different pathways throughout the course of the disease process, one of the most important is via the activation of innate immunity.3 P. acnes is thought to instigate an inflammatory cytokine response via activation of toll-like receptor (TLR)-2,3 which triggers a proinflammatory cytokine pattern.1-7
However, we are now discovering that subclinical inflammation is present at the onset of disease and it is not only driven by P. acnes. Studies by Jeremy et al and others have shed light on the concept of early preclinical inflammation in acne8 that typically persists throughout the acne lesion life cycle.6-7 They have documented a prelesional folliculocentric inflammatory phase of acne, evidenced by markedly increased numbers of CD4+ T lymphocytes; numbers of macrophages; upregulated expression of perifollicular IL-1; and upregulation of epidermal expression of α-integrins. These mediators are elevated in both normal skin and early papules of subjects with acne compared with normal skin of subjects without acne. Additionally, in subjects with acne, lesions had increased inflammatory mediators relative to uninvolved skin. Those mediators are also part of the immune system activation. More importantly, they were able to show that prelesional inflammation preceded follicular hyperkeratinization and the presence of microcomedones.8 These findings suggest that the so-called